成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. GPCR/G Protein Immunology/Inflammation Anti-infection
  3. CXCR HIV
  4. Plerixafor

Plerixafor  (Synonyms: 普樂沙福; AMD 3100; JM3100; SID791)

目錄號: HY-10046 純度: 99.90%
COA 產(chǎn)品使用指南

Plerixafor (AMD 3100) 是選擇性的 CXCR4 拮抗劑，IC50 為 44 nM。Plerixafor 是一種免疫刺激劑和造血干細胞動員劑，也是 CXCR7 的變構(gòu)激動劑。Plerixafor 抑制 HIV-1 和 HIV-2 的復(fù)制，EC50 為 1-10 nM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

我們將采用定制合成服務(wù)的方式為您快速提供所需產(chǎn)品和技術(shù)服務(wù)

Plerixafor Chemical Structure

Plerixafor Chemical Structure

CAS No. : 110078-46-1

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
5 mg ￥431
In-stock
10 mg ￥690
In-stock
50 mg ￥2050
In-stock
100 mg ￥3650
In-stock
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Plerixafor:

MCE 顧客使用本產(chǎn)品發(fā)表的 67 篇科研文獻

RT-PCR
WB
IF
Proliferation Assay
IHC

    Plerixafor purchased from MCE. Usage Cited in: Cancer Lett. 2022 Oct 7;551:215944.  [Abstract]

    Viability of cells treated with combinations different concentrations of AMD3100 and Olaparib for 24 h.

    Plerixafor purchased from MCE. Usage Cited in: Cancer Lett. 2022 Oct 7;551:215944.  [Abstract]

    Immunohistochemical staining of proliferation-related protein, Ki-67, in breast cancer after treatment with control, AMD3100 (2.5 mg/kg), Olaparib, or a combination of AMD3100 and Olaparib.

    Plerixafor purchased from MCE. Usage Cited in: Cell Death Dis. 2022 Feb 4;13(2):118.  [Abstract]

    PGK1 induced the CXCR4-mediated phosphorylation of AKT (p-AKT) and ERK (p-ERK), and blockade of CXCR4 signaling by AMD3100 (48?h) treatment did not alter cellular PGK1 expression in KIRC cells.

    Plerixafor purchased from MCE. Usage Cited in: Bioact Mater. 2021 Jan 7;6(7):2039-2057.  [Abstract]

    Western blot analysis of the expression of CXCR4, integrin αvβ3, p-Jak2, Jak2, p-FAK, FAK, p-STAT3 and STAT3 in MSCs (pretreated with a CXCR4 inhibitor (AMD3100; 20 μM; pretreated with 1 h) and an integrin αvβ3 inhibitor (cyclo(-RGDfK))) after the addition of 152RM for 24 h.

    Plerixafor purchased from MCE. Usage Cited in: Theranostics. 2021 Jan 1;11(6):2612-2633.  [Abstract]

    Transwell assays indicated that AMD3100 treatment (1 μg/ml, 24 hours) significantly decreases the migration and invasion of Caco-2-HOXB5 cells.

    Plerixafor purchased from MCE. Usage Cited in: Theranostics. 2021 Jan 1;11(6):2612-2633.  [Abstract]

    Caco-2 cells are incubated with vehicle or AMD3100 (1 μg/ml, 24 hours) after lentivirus transfection (LV-HOXB5), then Western blotting assays are conducted to measure the protein levels of CXCL12, HOXB5, CXCR4, p-ERK and p-ETS1 in the indicated cell lines.

    Plerixafor purchased from MCE. Usage Cited in: Adv Funct Mater. 2020, 2000309.

    NOD/SCID mice were i.p. injected with AMD3100 (4 mg/kg). After 1 h, the mice are i.v. injected with iFluor 647-labeled Aazo@CMSN. At 12 h after nanoparticle injection, the mouse craniums are excised for the observation of nanoparticle bone marrow niches targeting under CLSM. Pre-treatment with AMD3100 significantly declined the bone marrow niches targeting of the nanoparticles.

    Plerixafor purchased from MCE. Usage Cited in: Cell Mol Immunol. 2020 Mar;17(3):283-299.  [Abstract]

    ELISA of IL-1β in supernatants of BV2 cells stimulated with gp120 LAV (0.5?μg/mL) for 24 h in the presence of increasing doses of a CXCR4-specific inhibitor (AMD3100, 0.1-10?μM; prestimulated with 30?min-2?h).

    Plerixafor purchased from MCE. Usage Cited in: Oncogene. 2019 Jun;38(25):5021-5037.  [Abstract]

    IF staining of the tumor tissue sections showed decreased Ki67 and a reversal of EMT markers indicated by increased E-cadherin and decreased N-cadherin expression in the AMD3100 (5?mg/kg or 3.5?mg/kg) treated groups.

    Plerixafor purchased from MCE. Usage Cited in: Oncogene. 2019 Jun;38(25):5021-5037.  [Abstract]

    Additional EMT-related proteins (Snail and Slug) are downregulated by AMD3100 (5?mg/kg or 3.5?mg/kg) in tumor samples from both diet groups, as quantified by immunoblotting.

    Plerixafor purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2018;46(3):890-906.  [Abstract]

    The protein expression of LRRC4, SDF-1, CXCR4, ERK, Slit2 and VEGF in the brain tissue of rats is determined by Western blotting.

    Plerixafor purchased from MCE. Usage Cited in: Int J Biol Sci. 2017 May 5;13(5):604-614.  [Abstract]

    Epithelial cells with or without AMD3100 pretreatment are cultured in conditioned medium (CM) from LPS-treated NFs or LTA-treated NFs for 3 days, and the secretion of TNF-α in the supernatant of culture is detected by ELISA. Epithelial cells cultured in MSM are used as control. Both LPS-treated NFs and LTA-treated NFs enhanced the section of TNF-α by epithelial cells compared with control. Pretreatment of epithelial cells with AMD3100 significantly attenuates the increase of TNF-α.

    查看 CXCR 亞型特異性產(chǎn)品:

    查看 HIV 亞型特異性產(chǎn)品:

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM[1][2][3][4][7].

    IC50 & Target[3][7]

    125I-CXCL12-CXCR4

    44 nM (IC50)

    125I-CXCL12-CXCR7

     

    HIV-1

    1-10 nM (EC50)

    HIV-2

    1-10 nM (EC50)

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    CEM-SS CC50
    > 5 μM
    Compound: AMD-3100
    Cytotoxicity against human CEM-SS cells by MTT assay
    Cytotoxicity against human CEM-SS cells by MTT assay
    		[PMID: 19356827]
    CHO IC50
    0.051 μM
    Compound: AMD3100
    Competitive binding affinity to CXCR4 receptor (unknown origin) expressed in CHO cells incubated for 40 mins by 12G5 antibody based fluorescence analysis
    Competitive binding affinity to CXCR4 receptor (unknown origin) expressed in CHO cells incubated for 40 mins by 12G5 antibody based fluorescence analysis
    		[PMID: 30978562]
    CHO IC50
    65 nM
    Compound: AMD3100
    Binding affinity to CXCR4 (unknown origin) expressed in CHO cells measured after 40 mins by 12G5 antibody competition assay
    Binding affinity to CXCR4 (unknown origin) expressed in CHO cells measured after 40 mins by 12G5 antibody competition assay
    		[PMID: 27658790]
    HEK293 IC50
    2.3 nM
    Compound: AMD-3100
    Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    		[PMID: 19451305]
    HEK293 IC50
    213.1 nM
    Compound: 1; AMD3100
    Displacement of [125I]CXCL12 from human CXCR4 expressed in HEK293 cell membranes after 1.5 hrs by Topcount method
    Displacement of [125I]CXCL12 from human CXCR4 expressed in HEK293 cell membranes after 1.5 hrs by Topcount method
    		[PMID: 29314840]
    HEK293 IC50
    4.6 nM
    Compound: AMD-3100
    Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    		[PMID: 19451305]
    HEK293 IC50
    5.3 nM
    Compound: AMD-3100
    Antiviral activity against multidrug resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    Antiviral activity against multidrug resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    		[PMID: 19451305]
    HEK293 IC50
    6.2 nM
    Compound: AMD-3100
    Antiviral activity against HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    Antiviral activity against HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    		[PMID: 19451305]
    HEK293 IC50
    7 nM
    Compound: AMD-3100
    Antiviral activity against NNRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    Antiviral activity against NNRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    		[PMID: 19451305]
    HEK293 IC50
    9 nM
    Compound: AMD-3100
    Antiviral activity against NRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    Antiviral activity against NRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    		[PMID: 19451305]
    HEK293 IC50
    9.2 nM
    Compound: AMD-3100
    Antiviral activity against PI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    Antiviral activity against PI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days
    		[PMID: 19451305]
    MT4 CC50
    > 10 μg/mL
    Compound: AMD-3100
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23157587]
    MT4 CC50
    > 421 μM
    Compound: 1, AMD-3100
    Cytotoxicity against human MT4 cells after 4 days by MTT method
    Cytotoxicity against human MT4 cells after 4 days by MTT method
    		[PMID: 20043638]
    MT4 CC50
    > 421 μM
    Compound: 10d
    Concentration required to reduce the viability of mock infected cells by 50%
    Concentration required to reduce the viability of mock infected cells by 50%
    		[PMID: 8568797]
    MT4 CC50
    > 50 μM
    Compound: AMD3100
    Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine
    Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine
    		[PMID: 26094944]
    MT4 CC50
    > 50 μM
    Compound: AMD3100
    Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
    Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
    		[PMID: 26094944]
    MT4 CC50
    > 50 μM
    Compound: AMD3100
    Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine
    Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine
    		[PMID: 26094944]
    MT4 CC50
    > 50 μM
    Compound: AMD3100
    Cytotoxicity against in human MT-4 after 5 days by MTT assay
    Cytotoxicity against in human MT-4 after 5 days by MTT assay
    		[PMID: 33316719]
    MT4 CC50
    > 50 μM
    Compound: AMD3100
    Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    		[PMID: 32305183]
    MT4 CC50
    > 50 μM
    Compound: AMD3100
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 26094944]
    MT4 EC50
    0.004 μM
    Compound: 1, AMD-3100
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay
    		[PMID: 20043638]
    MT4 EC50
    0.008 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.008 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.008 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound
    Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.014 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 IC50
    0.017 μg/mL
    Compound: AMD-3100
    Antiviral activity against X4 HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of viral replication pre-incubated for 30 mins measured 5 days post infection by MTT assay
    Antiviral activity against X4 HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of viral replication pre-incubated for 30 mins measured 5 days post infection by MTT assay
    		[PMID: 23157587]
    MT4 EC50
    0.025 μM
    Compound: AMD3100
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine
    		[PMID: 26094944]
    MT4 EC50
    0.028 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.032 μM
    Compound: AMD3100
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 26094944]
    MT4 EC50
    0.034 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18378713]
    MT4 EC50
    0.039 μM
    Compound: AMD3100
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine
    Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine
    		[PMID: 26094944]
    MT4 EC50
    0.049 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    0.056 μM
    Compound: AMD3100
    Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound
    Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound
    		[PMID: 18378713]
    MT4 EC50
    10 μM
    Compound: 37
    Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells
    Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells
    		[PMID: 9925728]
    MT4 EC50
    2 nM
    Compound: AMD3100; 15c; 16c
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26974376]
    MT4 EC50
    2 nM
    Compound: AMD3100; 15c; 16c
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26974376]
    MT4 CC50
    6.5 μM
    Compound: AMD-3100
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 19356827]
    PBMC CC50
    > 10 μg/mL
    Compound: AMD-3100
    Cytotoxicity against human PBMC cells by MTT assay
    Cytotoxicity against human PBMC cells by MTT assay
    		[PMID: 23157587]
    體外研究
    (In Vitro)

    CXCR4 抑制劑 Plerixafor (AMD3100) 是一種有效的 CXCL12 介導(dǎo)的趨化性抑制劑 (IC50，5.7 nM)，效力略優(yōu)于其對 CXCR4 的親和力。Plerixafor 干擾 CXCR4 與其天然配體 SDF-1 (CXCL12) 的相互作用。用 CCX771 或 CXCL11 處理細胞對 CXCL12 介導(dǎo)的 MOLT-4 或 U937 TEM 沒有影響。相反，10 μM Plerixafor 在兩種細胞系中抑制 CXCL12 介導(dǎo)的 TEM[1]。
    Plerixafor 可防止腫瘤相關(guān)巨噬細胞 (TAM) 浸潤到腫瘤組織中[8]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    Plerixafor (2 mg/kg) 對 UUO 小鼠給藥會加劇腎間質(zhì) T 細胞浸潤，導(dǎo)致促炎細胞因子 IL-6 和 IFN-γ 的產(chǎn)生增加，并降低抗炎細胞因子 IL-10 的表達[5]。
    CXCR4 拮抗劑 Plerixafor (AMD3100) 在 8 周時顯著減少了血管周圍和間質(zhì)纖維化[6]。LD50，小鼠，SC：16.3 mg/kg；LD50，大鼠，SC：>50 mg/kg；LD50，小鼠和大鼠，靜脈注射：5.2 mg/kg[5]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    502.78

    Formula

    C28H54N8
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    普樂沙福
    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細胞實驗： 

    Ethanol 中的溶解度 : 50 mg/mL (99.45 mM; 超聲助溶)

    DMSO 中的溶解度 : 1.92 mg/mL (3.82 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCL and heat to 60°C; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.9889 mL 9.9447 mL 19.8894 mL
    5 mM 0.3978 mL 1.9889 mL 3.9779 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 3 mg/mL (5.97 mM); 澄清溶液

      此方案可獲得 ≥ 3 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 30.0 mg/mL 的澄清 EtOH 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% EtOH    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 3 mg/mL (5.97 mM); 澄清溶液

      此方案可獲得 ≥ 3 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 30.0 mg/mL 的澄清 EtOH 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.90%

    參考文獻
    Cell Assay
    [2]

    U87MG cells are seeded in 96-well plates at the density of 6×103 cells in 200 μL/well and treated with CXCL12, Plerixafor or with peptide R. MTT (5 μg/mL) is added at each time point (24, 48, 72 h) during the final 2 h of treatment. After removing cell medium, 100 μL DMSO are added and optical densities measured at 595 nm with a LT-4000MS Microplate Reader. Measurements are made in triplicates from three independent experiments[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3][4]

    Mice[3]
    Male C57bl/6 mice (6-7 weeks old, weighing 20 g) are used. The animals are acclimated to the housing environment, which is SPF and had a temperature of 22°C and a 12h/12h light/dark cycle for a week. Then, they are randomly divided into following experimental groups, with 8 mice in each group: normal (no specific intervention), UUO+AMD3100 (mice received UUO surgery and 2 mg/kg AMD3100), and UUO+PBS (mice received UUO surgery and the same volume of PBS). AMD3100 and PBS are administered via intraperitoneal injection every day until sacrifice.
    Rats[4]
    The CXCR4 antagonist, AMD3100 dissolved in H2O, is delivered in the type 2 diabetic sand rat model at a dose of 6 mg/kg per day for 8 weeks. In complementary studies, the effect of CXCR4 antagonism (AMD3100 6mg/kg/d) on regulatory T cell numbers is examined. For these studies, AMD3100 or vehicle is delivered via minipump for a period of one week.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO / Ethanol 1 mM 1.9889 mL 9.9447 mL 19.8894 mL 49.7235 mL
    Ethanol 5 mM 0.3978 mL 1.9889 mL 3.9779 mL 9.9447 mL
    10 mM 0.1989 mL 0.9945 mL 1.9889 mL 4.9724 mL
    15 mM 0.1326 mL 0.6630 mL 1.3260 mL 3.3149 mL
    20 mM 0.0994 mL 0.4972 mL 0.9945 mL 2.4862 mL
    25 mM 0.0796 mL 0.3978 mL 0.7956 mL 1.9889 mL
    30 mM 0.0663 mL 0.3315 mL 0.6630 mL 1.6575 mL
    40 mM 0.0497 mL 0.2486 mL 0.4972 mL 1.2431 mL
    50 mM 0.0398 mL 0.1989 mL 0.3978 mL 0.9945 mL
    60 mM 0.0331 mL 0.1657 mL 0.3315 mL 0.8287 mL
    80 mM 0.0249 mL 0.1243 mL 0.2486 mL 0.6215 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Plerixafor
    目錄號：
    HY-10046
    需求量：